The US FDA has approved aficamten, a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Clinical evidence In a clinical study involving 282 patients, aficamten significantly improved exercise capacity and clinical outcomes over 24 weeks compared with placebo, demonstrating its effectiveness in improving functional status and reducing left ventricular outflow tract obstruction.
Dosage and administration Available in the form of tablets Recommended starting dose is 5 mg orally once daily Dosage is individualized based on echocardiographic assessments and clinical status Contraindications Rifampin Warnings and precautions Risk of heart failure Drug interactions leading to increased risk of heart failure or loss of effectiveness Adverse reaction Hypertension Did you find this…
